The US market for Hemostats and Sealants grew +6.1% YoY in Q120, up from the pace of Q419 despite the late appearance of COVD-19 in the last few weeks of the quarter. Growth was slightly higher in the Hemostats market, with +6.8% growth driven by relative strength in thrombin hemostats.
As reported in SmartTRAK Financial Dashboard, the US Hemostats and Sealants market had a growth rate of +6.1% in Q120. Leading the way in Q120 was Baxter* with +11.6% YoY growth and continued strength from Tisseel* and Artiss* fibrin sealants. Becton Dickinson* (BD) also posted strong gains as its relaunched Progel* and continued its resurgence in Q120. However, all manufacturers predicted that second-quarter results would be much worse since the full effect of surgery deferrals would be felt for the entire quarter. Some manufacturers warned that revenues were reduced as much as...
- Complete Market Overview
- Baxter Posts Another Strong Quarter
- Absorbable Hemostats Lead The Way
- Progel Pulls Up Biologic Sealants
- Q120 Market Events
The US Sealants market, which includes the Biologic, Fibrin and Synthetics segments, rose +5.1% YoY to $* in Q120. Fibrin sealants saw another quarter of solid growth, up 6.4% to...